Please login to the form below

Not currently logged in
Email:
Password:

EGFR

This page shows the latest EGFR news and features for those working in and with pharma, biotech and healthcare.

GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

the treatment of patients with metastatic non-small cell lung cancer (NSCLC), whose tumours have high PD-L1 expression and no EGFR or ALK mutations.

Latest news

More from news
Approximately 7 fully matching, plus 171 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... Our teams of clinical researchers

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Tagrisso’s growth as it moves earlier in the treatment pathway for EGFR-positive non-small lung cancer (NSCLC) and launches in new markets like China, plus possible label extensions for

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Similarly, in other cancers, EGFR mutations, NTRK fusions and ALK fusions are all used as biomarkers because they indicate patients are likely to respond well to targeted therapies. ... The questions being asked are, what does an individual’s

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    lung cancer NSCLC patients with low PD-L1 expression (1%, also without EGFR or ALK mutations) – a group that was once thought unlikely to benefit from these drugs.

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...